- Home
- VRCA vs ACET Comparison
VRCA vs ACET Comparison
Compare VRCA & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | ACET |
|---|---|---|
| Founded | 2013 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 69.6M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VRCA | ACET |
|---|---|---|
| Price | $5.82 | $7.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.00 | ★ $65.33 |
| AVG Volume (30 Days) | 116.1K | ★ 161.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.82 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $372.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.45 |
| 52 Week High | $9.82 | $9.05 |
Technical Indicators
Market Signals| Indicator | VRCA | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 60.67 |
| Support Level | $5.22 | $7.70 |
| Resistance Level | $6.44 | $8.46 |
| Average True Range (ATR) | 0.39 | 0.45 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 59.03 | 89.82 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.